C19061501-F

Denali Therapeutics' DNL343, an eIF2B inhibitor, failed to meet primary and key secondary endpoints in a Phase 2/3 trial for amyotrophic lateral sclerosis (ALS) at 24 weeks.

Denali Therapeutics' DNL343, an eIF2B agonist, did not meet the primary endpoint of slowing ALS disease progression in a Phase 2/3 trial.

Sanofi reported a robust 15.7% sales growth in Q3, fueled by strong vaccine sales and the continued success of Dupixent, with sales up 23.8% to €3,476 million.

Sanofi and Denali Therapeutics have discontinued the Phase 2 K2 clinical trial of oditrasertib in multiple sclerosis due to its failure to meet primary and key secondary endpoints.

Sanofi and Denali Therapeutics' investigational drug SAR443820 (DNL788), a RIPK1 inhibitor, did not meet the primary endpoint in a Phase 2 clinical trial for amyotrophic lateral sclerosis (ALS).